Referencing Approved Drug Products in ANDA Submissions

On 27 October 2020 the FDA announced the availability of the final guidance for industry.

This guidance is intended to provide information to potential applicants on how to identify a reference listed drug (RLD), reference standard, and the basis of submission in an abbreviated new drug application (ANDA) submission.

Read more online 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /